Compare Illinois Tool Works Inc. (ITW) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Novavax Inc — how do they compare? Illinois Tool Works Inc. trades at $272.33 (market cap $78.17B), while Novavax Inc trades at $8 (market cap $1.30B). The key difference: Illinois Tool Works Inc. is far larger — about 60.1× Novavax Inc's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ITW | NVAX | |
|---|---|---|
Market Cap | $78.17B | $1.30B |
Sector | Industrials | Health |
52-Week High | $299.60 | $11.19 |
52-Week Low | $241.07 | $6.22 |
Enterprise Value | $86.49B | $800.50M |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $271.58, down 1.62% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 19.32% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights mixed sentiment, with some analysts citing premium valuation concerns while others note growth prospects from enterprise initiatives and a potential bullish chart pattern.
Outlook remains cautiously optimistic with a consensus price target of $288.25 offering ~6% upside. Key risks include valuation sensitivity, organic sales pressure in some segments, and macroeconomic headwinds. The upcoming Q2 2026 earnings report on July 28, 2026, will be critical for validating growth trajectory amid analyst divergence.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
